FTC continues campaign against reverse payments
In its latest bid to curb reverse payments between innovator pharmaceutical companies and generics, the US Federal Trade Commission has filed a complaint against Solvay Pharmaceuticals and three generic drug makers
The FTC complaint alleges that Watson Pharmaceuticals, Par Pharmaceuticals and Paddock Laboratories agreed to abandon their Abbreviated New Drug Application (ANDA) with the...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.